spravato fda - Search News

FDA approves Spravato

UPI News on MSN · 2d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.

FDA approves Spravato as first stand-along nasal spray to treat drug-resistant depression

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Hosted on MSN6m

Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results